Paul Glavine, Chief Growth Officer at Cybin Inc. (CYBN), made a significant purchase of the company's stock on September 9, 2026. Glavine acquired 90,000 shares at a price of $11.59 per share, representing a total investment of approximately $1.04 million.
This acquisition by a senior executive is often interpreted as a signal of strong confidence in the company's future prospects. The purchase comes shortly after another notable buy by the same insider in late August.
Cybin Inc. operates in the biotechnology sector, focusing on the development of psychedelic therapeutics. Investors often view insider buying activity as a positive indicator, suggesting that those with intimate knowledge of the company believe its valuation is attractive.